Supplementary Figure S2 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition
Publication
, Other
Shattuck-Brandt, RL; Chen, S-C; Murray, E; Johnson, CA; Crandall, H; O'Neal, JF; Al-Rohil, RN; Nebhan, CA; Bharti, V; Dahlman, KB; Ayers, GD ...
March 31, 2023
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Shattuck-Brandt, R. L., Chen, S.-C., Murray, E., Johnson, C. A., Crandall, H., O’Neal, J. F., … Richmond, A. (2023). Supplementary Figure S2 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. https://doi.org/10.1158/1078-0432.22468088.v1
Shattuck-Brandt, Rebecca L., Sheau-Chiann Chen, Emily Murray, Christopher Andrew Johnson, Holly Crandall, Jamye F. O’Neal, Rami Nayef Al-Rohil, et al. “Supplementary Figure S2 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition,” March 31, 2023. https://doi.org/10.1158/1078-0432.22468088.v1.
Shattuck-Brandt RL, Chen S-C, Murray E, Johnson CA, Crandall H, O’Neal JF, et al. Supplementary Figure S2 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. 2023.
Shattuck-Brandt, Rebecca L., et al. Supplementary Figure S2 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. 31 Mar. 2023. Crossref, doi:10.1158/1078-0432.22468088.v1.
Shattuck-Brandt RL, Chen S-C, Murray E, Johnson CA, Crandall H, O’Neal JF, Al-Rohil RN, Nebhan CA, Bharti V, Dahlman KB, Ayers GD, Yan C, Kelley MC, Kauffmann RM, Hooks M, Grau A, Johnson DB, Vilgelm AE, Richmond A. Supplementary Figure S2 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. 2023.